Embecta Corp. to Host Conference Call for Fiscal Q1 2026 Financial Results and Operational Update

Embecta Corp. will host a conference call on February 5, 2026, to discuss Q1 financial results and operations.

Quiver AI Summary

Embecta Corp., a company with a century-long history in insulin delivery, is set to host a conference call on February 5, 2026, at 8:00 a.m. ET to discuss its fiscal first quarter 2026 financial results and provide an operational update. The call will also include a question and answer session. Participants can access the live webcast through the company’s investor relations website or by teleconference. A replay of the call will be available later that day and archived for a year. Embecta is focused on expanding its role as a broad-based medical supplies company, with around 2,000 employees committed to enhancing lives through innovative solutions.

Potential Positives

Embecta Corp. is hosting a conference call to discuss its fiscal first quarter 2026 financial results, indicating transparency and a commitment to keeping stakeholders informed.
The focus on transitioning from a legacy in insulin delivery to a broader medical supplies company signals a strategic expansion that could open new market opportunities.
The company highlights its commitment to innovation and partnerships, which may enhance its reputation and drive future growth.

Potential Negatives

Absence of specific financial metrics or performance indicators may raise concerns among investors about the company's current fiscal health.
The shift from a focused insulin delivery company to a broad-based medical supplies company may create uncertainties around the company's strategic direction and market positioning.
Lack of detail regarding future growth strategies or operational improvements may lead to questions about the company's competitiveness in the evolving medical supplies sector.

FAQ

When is Embecta Corp's conference call for Q1 2026 financial results?

Embecta Corp's conference call will be held on Thursday, February 5, 2026, at 8:00 a.m. ET.

How can I participate in the Embecta conference call?

You can participate via the live webcast or access the teleconference using the provided links in the announcement.

Where can I find the replay of the conference call?

A replay of the conference call will be available on the embecta investor relations website starting at 11:00 a.m. ET on February 5, 2026.

What is Embecta's focus as a company?

Embecta is focused on advancing its legacy in insulin delivery and expanding into a broad-based medical supplies company.

How can I stay updated on Embecta's news and updates?

You can visit embecta.com or follow Embecta on social media platforms like LinkedIn, Facebook, and Instagram.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$EMBC Revenue

$EMBC had revenues of $264M in Q4 2025. This is a decrease of -7.72% from the same period in the prior year.

You can track EMBC financials on Quiver Quantitative's EMBC stock page.

$EMBC Hedge Fund Activity

We have seen 121 institutional investors add shares of $EMBC stock to their portfolio, and 171 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JEFFERIES FINANCIAL GROUP INC. added 542,162 shares (+40.4%) to their portfolio in Q3 2025, for an estimated $7,649,905
SG AMERICAS SECURITIES, LLC added 435,842 shares (+inf%) to their portfolio in Q4 2025, for an estimated $5,177,802
MILLENNIUM MANAGEMENT LLC removed 388,531 shares (-21.3%) from their portfolio in Q3 2025, for an estimated $5,482,172
QUBE RESEARCH & TECHNOLOGIES LTD removed 362,935 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $5,121,012
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC removed 312,857 shares (-15.7%) from their portfolio in Q3 2025, for an estimated $4,414,412
MORGAN STANLEY removed 303,019 shares (-25.1%) from their portfolio in Q3 2025, for an estimated $4,275,598
BALYASNY ASSET MANAGEMENT L.P. removed 298,809 shares (-93.8%) from their portfolio in Q3 2025, for an estimated $4,216,194

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$EMBC Analyst Ratings

Wall Street analysts have issued reports on $EMBC in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 09/05/2025

To track analyst ratings and price targets for $EMBC, check out Quiver Quantitative's $EMBC forecast page.

Full Release

PARSIPPANY, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal first quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 5, 2026.

Those who would like to participate may access the live webcast here , or access the teleconference here . The live webcast can also be accessed via the company’s website at investors.embecta.com .

A webcast replay of the call will be available beginning at 11:00 a.m. ET on February 5, 2026, via the embecta investor relations website and archived on the website for one year.

About embecta

embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn , Facebook , and Instagram .

Contacts:
Media Christian Glazar Sr. Director, Corporate Communications 908-821-6922 Contact Media Relations	Investors Pravesh Khandelwal VP, Head of Investor Relations 551-264-6547 Contact IR